Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor

NCT07442292 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07442292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07442292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
June 30, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc), lung cancer (sclc), melanoma (skin cancer), melanoma metastatic, pd-l1, pet / ct